The Biden administration on Friday named 15 top-selling drugs that will be included in a second round of price negotiations between Medicare and pharmaceutical companies.
On the list are semaglutide, a metabolic disease drug Novo Nordisk sells as Ozempic, Rybelsus and Wegovy, as well as four drugs for cancer, including Pfizer’s breast cancer treatment Ibrance.
This is breaking news. Read our full story for more details.